Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe
coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Background In May, 2022, several European countries reported autochthonous cases of
monkeypox, which rapidly spread globally. Early reports suggest atypical presentations. We …

The development of more recently approved drugs that cannot be tested as monotherapy
precludes assessment of the impact of resistance on antiretroviral activity that is not seriously …

Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …

Highly active antiretroviral therapy (HAART) results in potent and durable suppression of
HIV-1 viremia. However, HIV-1 replication resumes if therapy is interrupted 1 , 2 . Although it is …

Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …

The 2017 edition of the IAS–USA drug resistance mutations list updates the figures last
published in November 2015. The mutations listed are those that have been identified by specific …

Context Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-1)
drug resistance mutations may adversely affect response to antiretroviral treatment (ART), …